Lv1
40 积分 2023-04-11 加入
A BCMA-Targeted Bispecific Antibody Is Active in Multiple Myeloma
1天前
待确认
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
2天前
已完结
48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
3天前
已完结
P1.12-18 Nonclinical Safety Assessment of AMG 757, a DLL3 Bispecific T Cell Engager, in the Cynomolgus Monkey
3天前
已完结
Discovery of a fully human antibody to the proximal membrane terminus of MUC1 based on a B-cell high-throughput screening technique
17天前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
19天前
已完结
Structural basis of assembly of the human T cell receptor–CD3 complex
19天前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
24天前
已完结
Abstract 3495: QL535, A novel CD2-costimulating T cell engager targeting PSMA-positive prostate cancer matching CD28 trispecific antibody in cytotoxicity, minimizing cytokine release and T-cell exhaustion
1个月前
已完结
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
1个月前
已完结
皖公网安备34019202002308
